Table 2.
Systemic therapy during the period of SARS-CoV-2 infection
| Diagnoses | Patients with SARS-CoV-2 diagnosis within 30 days prior to chemotherapy | Patients with SARS-CoV-2 diagnosis within 30 days after the chemotherapy | ||
|---|---|---|---|---|
| Number of patients | Chemotherapy protocol—number of patients | Number of patients | Chemotherapy protocol—number of patients | |
| Acute lymphoblastic leukemia | 7 | Protocol I—1; protocol II—6 | 20 | Protocol I—3; protocol M—3; protocol HR—3; protocol II—7; maintenance therapy—3; relapsed—1 |
| CNS tumor | 1 | VCR + VP-16 + CTX—1 | 15 | VCR + cisplatin—3; VCR—2; VCR + VP-16 + CTX—1; VCR + cisplatin + CCNU—1; protocol 4 (week 8; week 29)- 2; protocol 3 (cycle 2)—1; VBL—2; Protocol 1 HRG—1; temozolomide + cisplatin—1; radiotherapy—1 |
| Soft tissue sarcoma | – | – | 13 | IVAd3-1; VCR-ADM-CTX-1; gemcitabine + vinorelbine—1; I2VAdr-1; ACCTTIVE-1; I3VActd-1; idarubicin + trofosfamide -1; radiotherapy—2; I2VE-1; I2VA-1; TECC -1; VAC—1 |
| Neuroblastoma | 2 | Topotecan + dacarbazine—1; topotecan—1 | 2 | COJEC-A—1; radiotherapy—1 |
| Hodgkin lymphoma | – | – | 5 | AVD—2; COPDAC—2; DECOPDAC 21—1; OEPA—1 |
| Renal tumor | – | – | 3 | VCR + ACTD—1; doxorubicin + CTX—1; bevacizumab -1 |
| Acute myeloid leukemia | – | – | 2 | Induction AIE—1; Ida-FLA—1 |
| Non-Hodgkin lymphoma | - | – | 2 | R-CYM—1; VBL—1 |
| Osteosarcoma | – | - | 2 | HD MTX—1; AP (week 1)—1 |
| Retinoblastoma | 1 | Topotecan—1 | – | – |
| Other (EWS, GCT, LCH, NET, HCC, SPN) | 1 | Sorafenib—1 | 4 | VAC—1; VBL—1; gemcitabine 1 g/m2—1 |
Details on chemotherapy protocols are presented in Additional file 1
ACTD, actinomycin-D; CCNU, lomustine; CTX, cyclophosphamide; EWS, Ewing’s sarcoma; GCT, germ cell tumor; HCC, hepatocellular carcinoma; IFO, ifosfamide; LCH, Langerhans histiocytosis; MTX, methotrexate; NET, neuroendocrine tumor; SPN, solid pseudopapillary neoplasm; VCR, vincristine; VP-16, etoposide